Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(49,013) | $(40,798) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 537 | 513 |
| Stock-based compensation | 8,715 | 9,059 |
| Accretion of discount on marketable securities, net | (1,013) | (1,923) |
| Amortization of right-of-use asset | 53 | 41 |
| Changes in assets and liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s D&A?
- Edgewise Therapeutics, Inc. (EWTX) reported D&A of $537K in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s D&A changed year-over-year?
- Edgewise Therapeutics, Inc.'s D&A increased by 4.7% year-over-year, from $513K to $537K.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s D&A has grown at a 60.4% compound annual growth rate (CAGR), from $308K to $2.04M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Edgewise Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude